Author:
Ocaña Alberto,Amir Eitan,Pandiella Atanasio
Abstract
Abstract
Background
There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).
Methods
Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.
Results
We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).
Conclusions
We suggest potential mechanisms to optimize these compounds and their future clinical implementation.
Funder
ACEPAIN, Diputación de Albacete, ISCIII and CRIS Cancer
Publisher
Springer Science and Business Media LLC
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献